GlassScriptPhysician profile
Natalee Kay Wilson
NPI 1609396126
$6,851.77
in general payments reported to CMS, 2019-2025
32 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $969 · 2023: $1,996 · 2024: $2,013 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,883.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,435.63 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,118.25 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $852.90 | 2023-2025 | Vraylar, Synthroid |
| Lilly USA, LLC | $581.06 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $562.40 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $379.16 | 2023-2025 | |
| Amgen INC. | $251.90 | 2022-2024 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $223.14 | 2023-2025 | |
| Exact Sciences Corporation | $212.82 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $169.68 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.75 | 2023-2025 | Ofev, Jardiance |
| Abbott Laboratories | $113.53 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $111.91 | 2022-2024 | |
| Astellas Pharma US INC | $105.90 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $103.92 | 2023-2025 | Accrufer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $98.04 | 2023-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $61.60 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $54.82 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.44 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $27.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.23 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.40 | 2023 | |
| Ibsa Pharma INC. | $20.41 | 2025 | Flector, Licart, Tirosint |
| Viiv Healthcare Company | $19.38 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.35 | 2024 | Caplyta |
| Tris Pharma INC | $17.85 | 2024 | Dyanavel Xr |
| Pulmonx Corporation | $16.32 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Sumitomo Pharma America, INC. | $15.26 | 2024 | Gemtesa |
| Currax Pharmaceuticals LLC | $14.81 | 2023 | Contrave |
| Xeris Pharmaceuticals, INC. | $13.84 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $12.94 | 2023 | Watchman Flx |
| Sonex Health, INC. | $11.95 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalee Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.